Oxaliplatin

Catalog No.S1224 Synonyms: L-OHP

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

Cited by 22 Publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Gastroenterology, 2017, 153(4):1082-1095

PubMed: 28625833 ( click the link to review the publication )

Cancer Res, 2019, 79(17):4491-4502

PubMed: 31273064 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz032

PubMed: 31065671 ( click the link to review the publication )

Oncol Lett, 2019, 17(6):5023-5029

PubMed: 31186713 ( click the link to review the publication )

Oncol Lett, 2019, 5(3):935-942

PubMed: 23426424 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2018, 356:159-171

PubMed: 30086361 ( click the link to review the publication )

Int J Oncol, 2018, 53(2):844-854

PubMed: 29749542 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Theranostics, 2018, 8(5): 1312–1326

PubMed: 29507622 ( click the link to review the publication )

J Cancer, 2017, 8(17):3555-3566

PubMed: 29151941 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Cell, 2017, 170(3):548-563

PubMed: 28753429 ( click the link to review the publication )

Cancer Lett, 2016, 380(1):87-97

PubMed: 27322737 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1772-9

PubMed: 27613096 ( click the link to review the publication )

Int J Cancer, 2014, 136(4):E51-61

PubMed: 25156627 ( click the link to review the publication )

Ann Surg Oncol, 2014, 21(1):179-88

PubMed: 23907312 ( click the link to review the publication )

J Proteomics, 2014, 113:326-36

PubMed: 25451013 ( click the link to review the publication )

J Biomed Opt, 2014, 19(11):116001

PubMed: 25364948 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(12):2771-7

PubMed: 24093441 ( click the link to review the publication )

Optical Methods for Tumor Treatment and Detection, 2013, 10.1117/12.2010730

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

Targets

DNA synthesis ^[1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)

In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. ^[1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. ^[2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HKESC-2	NV73fpdvS3m2b4TvfIlkcXS7IFHzd4F6	NEjBSpEx6oDVMU[wxsDPxE1?	MW[0POKhcA>?		NIDEfVZKSzVyPUWuPOKhyrIEoECuOUDPxE1?	NFnobIYzPjR5NE[5Ny=>
CaES-17	NWTZR4xuS3m2b4TvfIlkcXS7IFHzd4F6	M1W1RVDjiJNzNkFCpO69VQ>?	M{LKcFQ5yqCq		MoLOTWM2OD13LkZCpOKyyqByLkKg{txO	NX;kO\|cxOjZ2N{S2PVM>
SW480	NIDudoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3qxXlQ5KGkEoB?=		M2DPdWlEPTB;MT64O{DPxE1?	M1jnVlI3OjZ7N{W5
HCT116	NX;VXpRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml;6OFghcMLi		M{jnTGlEPTB;MUGuPFYh\|ryP	M1Tqb\|I3OjZ7N{W5
LoVo	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1yyU\|Q5KGkEoB?=		NILp[IdKSzVyPUm0Mlg{KM7:TR?=	NYm5U4V4OjZ{Nkm3OVk>
SK-BR-3	M{LPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\4S41KSzVyPUOxMlAhyrFiMD6xJO69VQ>?	NXr5TIRmOjZ{MUG1PVE>
MCF-7	M2DaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfjN5JKSzVyPUG1MlQhyrFiMD6zJO69VQ>?	MkTsNlYzOTF3OUG=
MDA-MB-231	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTJ\|LkGgxtEhOC5zIN88US=>	M2LWcFI3OjFzNUmx
HCT116 p53+/+	MYPGeY5kfGmxbjDBd5NigQ>?	NXfYWoFROS93IN88US=>	MoX1NlQwPDhiaB?=		MVnpcoR2[2W\|IITyZY5{[3KrcITpc45idCC{ZYDy[ZN{cW:wIH;mJGRWXC2Q	Mn3ZNlYzODh3MkO=
LoVo	NULTO4w3TnWwY4Tpc44hSXO\|YYm=	NIXofpkyNzVizszN	Mnz2NlQwPDhiaB?=		MWLpcoR2[2W\|IITyZY5{[3KrcITpc45idCC{ZYDy[ZN{cW:wIH;mJGRWXC2Q	M4f1W\|I3OjB6NUKz
SNU-398	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrGTWM2OD14LkZCpOKyyqBzLkGg{txO	Mn;0NlYyPjB2Mkm=
Hep-G2	MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzGe4ZKSzVyPUGzMlHDqMLzwrCxMlYh\|ryP	MlTTNlYyPjB2Mkm=
SNU-475	NFy2dYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\OTWM2OO,:nkOwJO69VQ>?	M{HNN\|I3OTZyNEK5
SNU-387	NV35eHIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHr[4dEUUN3ME2yOeKhyrIEoEKuO{DPxE1?	M1y2UFI3OTZyNEK5
HT29	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPMTWM2OD1yLki4xsDDucLiMD6yJO69VQ>?	M4TMSVI3OTR6NUm2
HCT116	NGjsN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7JPYlKSzVyPUCuOFHDqMLzwrCwMlAzKM7:TR?=	MWmyOlE1QDV7Nh?=
PA-1	M1nnVWNmdGxiVnnhZoltcXS7IFHzd4F6	NVL1enRnOC1{MDFOwG0>	M4PxVFI1NzR6IHi=		M4DlR4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	M37NfVI3OTN6Nkex
OVCAR-5	NXHDTmtMS2WubDDWbYFjcWyrdImgRZN{[Xl?	NU\ZTVVEOC14MDFOwG0>	M3f1cVI1NzR6L{eyJIg>		NVTLO3RscW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NWjoW\|VoOjZzM{i2O\|E>
SK-OV-3	MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MojINE0yODBizszN	MWWyOE81QC95MjDo		NYHXNnRPcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MofCNlYyOzh4N{G=
PA-1	M3nSdmZ2dmO2aX;uJGF{e2G7	M1;3Z\|ExKM7:TdMg	MUGyOIg>		MlnleJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz	MnraNlYyOzh4N{G=
OVCAR-5	MVHGeY5kfGmxbjDBd5NigQ>?	Ml\0N\|Ah\|ryP	NGLqbos1QGh?		NHSyUnR1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM>	NFTK[oEzPjF\|OE[3NS=>
SK-OV-3	M2DCeGZ2dmO2aX;uJGF{e2G7	NIraVVk2OCEQvF2=	NXLCN5VFQTZiaB?=		MV\0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO=	MknaNlYyOzh4N{G=
PA-1	Mnn1SpVv[3Srb36gRZN{[Xl?	MmrzNVAh\|ryPwrC=	Ml61OFhp		MmPaeZAuemWpdXzheIV{KHSqZTDzeJJme3NibHnnZY5leyCob4KgUmsh[2WubD3hZ5RqfmG2aX7nJJJm[2WydH;yd{BidmRiVGLBTWwhemWlZYD0c5J{	M3rwZlI3OTN6Nkex
OVCAR-5	MYPGeY5kfGmxbjDBd5NigQ>?	NYTrXYh[OzBizszN	MmPLOFhp		MVn1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM>	MlruNlYyOzh4N{G=
SK-OV-3	NITMNnZHfW6ldHnvckBCe3OjeR?=	NF7qfWI2OCEQvF2=	MljiPVYhcA>?		NG[zWlh2eC2{ZXf1cIF1\XNidHjlJJN1emW\|czDsbYdidmS\|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN?	MmXhNlYyOzh4N{G=
PA-1	M2jae2Z2dmO2aX;uJGF{e2G7	MWmxNEDPxE4EoB?=	MYSyOIg>		Mn63dJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm\|aYO=	M3fy[\|I3OTN6Nkex
OVCAR-5	NXLHT5VSTnWwY4Tpc44hSXO\|YYm=	NIPyTpEzOCEQvF5CpC=>	NF7rOXQzPGh?		MYTwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?=	NWTJToJxOjZzM{i2O\|E>
SK-OV-3	NF3KeJNHfW6ldHnvckBCe3OjeR?=	NHK0[XY2OCEQvF5CpC=>	MkX5OFghcMLi		MYLwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?=	NUP3OmZuOjZzM{i2O\|E>
CT26	NV;6[HRmTnWwY4Tpc44hSXO\|YYm=	M2rOVVQhdU1?	MkXUOFghcMLi		MVXpcoR2[2W\|IHH1eI9xcGGpeR?=	MYOyOlE{PzBzMh?=
CT26	NUjqenExTnWwY4Tpc44hSXO\|YYm=	MUm0JI1O	NVfBSVNHPDhiaNMg		MkfubY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDheZRweGijZ4mtdoVt[XSnZDDwdo91\Wmwczygd5VkcCCjczDMR\|MuUUluIFLlZ4xqdjFiYX7kJGFVTzV?	M4XxelI3OTN5MEGy
CT26	NEm4dIxE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NV\He2Q2PCCvTR?=	NUHMToJCPDhiaNMg		MWTk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHlidH:gOVMvOiV?	MVeyOlE{PzBzMh?=
BE	MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLuW4FvUUN3ME2zMlM{KM7:TR?=	MWmyOlAzOzB6NR?=
Colo205	M4Ti[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWKyeZdpUUN3ME2zMlM{KM7:TR?=	NXzRXW5DOjZyMkOwPFU>
DLD1	NGHOZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPCWHZTUUN3ME2yMlAyKM7:TR?=	NVu3OXJNOjZyMkOwPFU>
HT29	NVO2cWpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4riZmlEPTB;Mj62PUDPxE1?	M3nDZlI3ODJ\|MEi1
HCT15	M1\DVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLHTWM2OD1zLkSzJO69VQ>?	MWmyOlAzOzB6NR?=
HCT116	M4fUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{frPGlEPTB;MT6wOEDPxE1?	NHHYNoMzPjB{M{C4OS=>
HCT116p53-	NXfpc3ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLKTWM2OD1zLkC4JO69VQ>?	MWmyOlAzOzB6NR?=
KM12	NYe2XG1ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTRwM{eg{txO	MXyyOlAzOzB6NR?=
LoVo	MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7jTWM2OD1zLkKg{txO	NYLuUG03OjZyMkOwPFU>
RKO	NVKxWmpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDmTWM2OD1zLkKzJO69VQ>?	NXfWepJlOjZyMkOwPFU>
SW480	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfGW45XUUN3ME2yMlg3KM7:TR?=	NGrmfm8zPjB{M{C4OS=>
SW620	NYTWSGlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDFd3lGUUN3ME2zMlY5KM7:TR?=	MX2yOlAzOzB6NR?=
MC38	NVLwPW1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLETWM2OD1{MzFOwG0hyrFiMh?=	MUKyOlAxPDB6NB?=
HT29	NEDUR\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTZ\|IN88UUDDuSBzOB?=	M4LMdFI3ODB2MEi0
DLD-1	NWK0b4N3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTN{LkKg{txO	Mki4NlYxODNyOEW=
HT-29	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTN3Lk[g{txO	MUKyOlAxOzB6NR?=
SiHa	NH7ZUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEG1ZpJKSzVyPUCuPEDDuSByLkGg{txO	M2fUR\|I2QDBzMEC3
S3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nsemlEPTB;NUOuOUDDuSBzLkWg{txO	NVKx[FgzOjV6MEGwNFc>
AGS	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7lTWM2OD1zMD62JO69VQ>?	MlXUNlU4QDlyNUe=
MKN-45	NVL4R4pbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHz5NmRKSzVyPUG0MlAh\|ryP	M4r2XFI2Pzh7MEW3
TMK-1	MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkG0TWM2OD1{Mj62JO69VQ>?	NGXYepEzPTd6OUC1Oy=>
SCM-1	NGC5W2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\LTZhIUUN3ME2xO{42KM7:TR?=	MUiyOVc5QTB3Nx?=
HCT-15	MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzxTWM2OD16Lk[0JO69VQ>?	MkDiNlU4PjF2N{m=
DiFi	NVvUOHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvpWYNKSzVyPUGwMlk2KM7:TR?=	MY[yOVc3OTR5OR?=
DLD-1	NYO5[nR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4P2ZmlEPTB;OD62OUDPxE1?	NVzNPGlFOjV5NkG0O\|k>
COLO-320DM	NHS4SYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{j4R2lEPTB;NT6zPEDPxE1?	NFvqNY0zPTd4MUS3PS=>
SNU-175	NEDoZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPVTWM2OD1zLkWxJO69VQ>?	M2T0WlI2PzZzNEe5
HT-29	Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfFOHZKSzVyPUWuNlIh\|ryP	M4jHVlI2PzZzNEe5
SW620	MmLnSpVv[3Srb36gRZN{[Xl?	NHnBeJEyOOLCidM1[{9udA>?	MXKyOQKBkWh?		MnTEbY5kemWjc3XzJGxEOy2LSTDhZ4N2dXWuYYTpc44h[W6mIHTlZ5Jm[XOnczDQOlIh\XiycnXzd4lwdg>?	NHLEb28zPTd2OUSyNC=>
SW480	NUjk[mhVTnWwY4Tpc44hSXO\|YYm=	MnnGNVDjiIoEtXevcYw>	Mk\NNlTjiImq		NGHPVoRqdmO{ZXHz[ZMhVEN\|LVnJJIFk[3WvdXzheIlwdiCjbnSg[IVkemWjc3XzJHA3OiCneIDy[ZN{cW:w	MljGNlU4PDl2MkC=
SW620	MWPGeY5kfGmxbjDBd5NigQ>?	NWrPNmU3OTEkgJpCuYcwdWx?	MV6yOQKBkWh?		NY\yNGIz\W6qYX7j[ZMh[2WubIXsZZIh[XW2b4DoZYdq[yCobIX4	NEjDOJgzPTd2OUSyNC=>
SW480	Ml7mSpVv[3Srb36gRZN{[Xl?	Mnn3NVDjiIoEtXevcYw>	MU[yOQKBkWh?		NV35OFB{\W6qYX7j[ZMh[2WubIXsZZIh[XW2b4DoZYdq[yCobIX4	NWrKVYVlOjV5NEm0NlA>
A549	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rURWlEPTB;NT64JOKyKDBwNjFOwG0>	M4DaWVI2PjJ3MkSz
A549/CDDP	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHEbIpKSzVyPUG4MlYhyrFiMT6yJO69VQ>?	NXPCUpZEOjV4MkWyOFM>
Panc-1	M1vZUWNmdGxiVnnhZoltcXS7IFHzd4F6	Mlv0NlUwPTBizszN	MknPNlQwPDhiaB?=		M4eyeolvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC\|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>?	NEW3UmszPTR2NEmxOC=>
MIAPaCa-2	MoHqR4VtdCCYaXHibYxqfHliQYPzZZk>	M130TlI2NzVyIN88US=>	M4LhOlI1NzR6IHi=		MWrpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy\|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E>	MWOyOVQ1PDlzNB?=
SW1990	M1rY[GNmdGxiVnnhZoltcXS7IFHzd4F6	MXSyOU82OCEQvF2=	M1zYZ\|I1NzR6IHi=		MmXpbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC	MUOyOVQ1PDlzNB?=
HPDE	NIHvWZRE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NUXuWlY3OjVxNUCg{txO	NVjVc3VDOjRxNEigbC=>		M2nnUolvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC\|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>?	NHTCdIszPTR2NEmxOC=>
Panc-1	M4LDSWFxd3C2b4Ppd{BCe3OjeR?=	M17HclI26oDLwsXN	MmP0NlQhcA>?		M4\EdYlv\HWlZYOgZZBweHSxc3nzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F?	MUGyOVQ1PDlzNB?=
MIAPaCa-2	NI\qXIxCeG:ydH;zbZMhSXO\|YYm=	Mo\BNlXjiIoEtV2=	M2jBVVI1KGh?		NUj1NW1PcW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?=	MVSyOVQ1PDlzNB?=
Panc-1	NUDoZoNLTnWwY4Tpc44hSXO\|YYm=	NETVWFYzPeLCidM1US=>	MVSyOE81QCCq		NHHXWZBqdmS3Y3XzJINt\WG4YXflJI9nKFCDUmCsJINie3Cjc3WtPUwh[2G\|cHHz[U05KGGwZDDjZZNx[XOnLURCpC=>	MnzENlU1PDR7MUS=
MIAPaCa-2	MXzGeY5kfGmxbjDBd5NigQ>?	NH61SJczPeLCidM1US=>	MYmyOE81QCCq		NYDjdJFqcW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG\|ZT2zxsA>	MUOyOVQ1PDlzNB?=
SW480	MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1vWVVczKGkEoB?=		M{G3W2lEPTB;MUCuO:KyOi5{NjFCuYcwdUx?	MYSyOVM3ODZ\|MR?=
HCT116	MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3i2SVczKGkEoB?=		NYXJZVJyUUN3ME22MlI{yrFyLke1JOK2\y:vTB?=	M37mVlI2OzZyNkOx
COC1	MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7lTHRNUUN3ME20Ok4zOMLiwsJCpFMvOTRizszN	M17EN\|I2OzB5NES4
SGC7901	NUfPZ4ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\TUYJKSzVyPUKxMlc{yqEEsdMgN{4xQCEQvF2=	NYDiNGFROjV\|MEe0OFg>
A549	Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37Jd2lEPTB;NUGuNFjDqMLzwrCxNE46PiEQvF2=	NVS0UYF4OjV\|MEe0OFg>
HepG2	MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXVZoJ6UUN3ME2xOE4zPMLiwsJCpFEvQDJizszN	NFnkdmUzPTNyN{S0PC=>
MCF-7	MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH[1V2lKSzVyPUG0MlI1yqEEsdMgNU45OiEQvF2=	NUjVOZgyOjV\|MEe0OFg>
HCT-116	M4T3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrGUWNKSzVyPU[uNlTDqMLzwrCyMlk4KM7:TR?=	MY[yOVMxPzR2OB?=
HT-29	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRjVyIN88US=>	NYi2N\|B6OjV\|MEe0OFg>
HEK293	NXvzfIFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\YOm12UUN3ME24MlgzyqEEsdMgOU42QSEQvF2=	M{jqTlI2OzB5NES4
HUVEC	NVnmTXVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13ENmlEPTB;MUGuN\|DDqMLzwrCxMlAzKM7:TR?=	NFe5Vm0zPTNyN{S0PC=>
SW480	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYixxsDPxE1?	NULzeYluOC15MjDo		NH\MS\|ZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>?	MmX2NlQ6QTd2NUG=
HT-29	NXzvd5RST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfMeVQyyqEQvF2=	MXGwMVczKGh?		MY\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	MVSyOFk6PzR3MR?=
HCT116	Mke2SpVv[3Srb36gRZN{[Xl?	M3nQfVIwPSEEtV2=	M3HKblI1NzR6IHi=		NGTY[Xp{fXCycnXzd4V{KHO3co\peolvKG2UTlGg[ZhxemW\|c3nvci=>	M2T0O\|I1PzZzNEGx
SW480	NGT4VoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUO0PEBpyqB?		NHLScIVKSzVyPUKwMlghfWdxbVy=	NVXwUppbOjR5MkC2O\|U>
SW620	NWDFN45QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPJcZZIOTBvN{CgcYcwVA>?	MnXoNlQwPDhxN{KgbC=>		M1;UOIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NFXCOnUzPDZ2NkOwOS=>
Caco2	MlHISpVv[3Srb36gRZN{[Xl?	NHH0VWM{OMLizszN	M1jvfFI1KGh?	MnPxSG1UVw>?	MkjEbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDIU{0yNCCDS2KxR{wh[W6mIF7RU\|E>	M2j3UVI1PTV4NEG1
Caco2	NXXQU21vTnWwY4Tpc44hSXO\|YYm=	MnjrN{8yOC9\|MDFOwG0>	MUKxOkBp	MUfEUXNQ	M4HnWolv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEGNUkHDNUwhVlGRMTygTG8uOSxiTWLQNkzDqGGwZF3SVFPDqGSxc3Wt[IVx\W6mZX70cJk>	NIraRmozPDV3NkSxOS=>
Caco2	M3nHUGZ2dmO2aX;uJGF{e2G7	NHXLeIY{OC9zMEFCpO69VQ>?	MYmxOuKhcA>?	NHX6[2xFVVOR	MVjhZ5RqfmG2ZYOgUpJnOg>?	MUSyOFU2PjRzNR?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	VEGFR-1 / NRP-1 ; PubMed: 18790786 Mol Cancer Ther HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); PubMed: 18790786 Mol Cancer Ther HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min. p-Src(Y418) / p-FAK(Y861) ; PubMed: 19383922 Cancer Res Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ	18790786 19383922
Immunofluorescence	E-cadherin / Vimentin; PubMed: 30787271 Cell Death Dis Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells. ATXN2L / G3BP1; PubMed: 30787271 Cell Death Dis Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules.	30787271
Growth inhibition assay	Cell viability ; PubMed: 28339092 Oncol Rep Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations.	28339092

In vivo

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. ^[6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C₂₆ colon carcinoma xenografts. ^[7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. ^[8]

Protocol

Cell Research:^[4]	+ Expand Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines Concentrations: ~100 μM Incubation Time: 48 hours Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO₂ and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 10³ cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control (Only for Reference)
Animal Research:^[6]	+ Expand Animal Models: Human hepatocellular carcinoma xenografts HCCLM3 Formulation: Water solution Dosages: 10 mg/kg Administration: A weekly i.p. injection (Only for Reference)

Cell Research:^[4]

+ Expand

Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
Concentrations: ~100 μM
Incubation Time: 48 hours
Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO₂ and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 10³ cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
(Only for Reference)

Animal Research:^[6]

+ Expand

Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
Formulation: Water solution
Dosages: 10 mg/kg
Administration: A weekly i.p. injection
(Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	Water	3 mg/mL warmed (7.55 mM)
	Ethanol	0.01 mg/mL (0.02 mM)
	DMF	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% glucose (with warming) For best results, use promptly after mixing.	3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Oxaliplatin SDF

Molecular Weight	397.29
Formula	C₈H₁₄N₂O₄Pt
CAS No.	61825-94-3
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	L-OHP

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04003792	Not yet recruiting	Drug: oxaliplatin\|Drug: FOLFIRI Protocol\|Drug: Bevacizumab	Liver Metastasis Colon Cancer	Rabin Medical Center	January 2020	Phase 2
NCT03872908	Not yet recruiting	Device: Chilled gloves\|Device: Surgical gloves	Breast Cancer\|Colorectal Cancer	Centre Leon Berard	June 15 2019	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is it ok to dissolve Oxaliplatin in DMSO?
Answer:
Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Blasticidin S HCl ^New

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
YK-4-279 ^New

YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).
Cisplatin

Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. DMF is recommended for dissolution.

Features:One of the most widely used and most potent chemotherapeutic agents.
Gemcitabine HCl

Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
Bleomycin Sulfate

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
Gemcitabine

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
Fluorouracil (5-Fluoracil, 5-FU)

Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.
Carboplatin

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Features:A DNA synthesis inhibitor.
Cytarabine

Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Choose Your Country or Region

By Signaling Pathways

By product type

Oxaliplatin

Cited by 22 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Oxaliplatin SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Choose Your Country or Region

By Signaling Pathways

By product type

Oxaliplatin

Cited by 22 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Oxaliplatin SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)